Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Overview of attention for article published in Alzheimer's Research & Therapy, April 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#14 of 1,334)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 51 news outlets

twitter: 11 X users

Citations

dimensions_citation: 31 Dimensions

Readers on

mendeley: 44 Mendeley

Summary News X Dimensions citations

So far, Dimensions has found 31 publications that cite this research output.

31

The most recent citing publications are shown below. View all 31 publications that cite this research output on Dimensions.

Clinical Relevance of Donanemab Treatment (S1.004)

Article in Neurology (April 2024)

Machine Learning and Digital Biomarkers Can Detect Early Stages of Neurodegenerative Diseases

Article in Sensors (February 2024)

Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer’s disease

Article in Alzheimer's Research & Therapy (February 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.